Literature DB >> 28693801

Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis.

Wing-Lok Chan1, Kwok-Keung Yuen2, Steven Wai-Kwan Siu2, Ka-On Lam3, Dora Lai-Wan Kwong3.   

Abstract

This review evaluated the efficacy, toxicities and quality of life of third-line systemic treatment (TLT) versus best supportive care (BSC) in metastatic gastric cancer patients after failing two lines of systemic treatment. Six studies were included, involving 890 participants (TLT: 587, BSC: 303, Asian: 679, 76.3%), median 53-61 years old, ECOG 0-1 with no major co-morbidities. Compared with BSC, TLT improved overall survival (HR 0.63; 95% CI 0.46-0.87, corresponding to an improvement in medial OS from 3.20 to 4.80 months), progression-free survival (HR 0.29; 95% CI 0.18-0.45), objective response rate (RR 5.28; 95% CI 1.00-27.83) and disease control rate (RR 4.51; 95% CI 2.64-7.71). The efficacy results favoring TLT should be interpreted with caution for the substantial heterogeneities, wide confidence intervals and selection bias. More toxicities occurred in the TLT arms. This review highlighted the paucity of QOL data. Future studies should focus more on QOL-related outcomes. PROSPERO registration: 2015 CRD42015017873.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Gastric cancer; Metastatic; Palliative care; Targeted therapy

Mesh：

Year:  2017        PMID： 28693801     DOI： 10.1016/j.critrevonc.2017.05.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  13 in total

1.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Authors:  Charles S Fuchs; Toshihiko Doi; Raymond W Jang; Kei Muro; Taroh Satoh; Manuela Machado; Weijing Sun; Shadia I Jalal; Manish A Shah; Jean-Phillipe Metges; Marcelo Garrido; Talia Golan; Mario Mandala; Zev A Wainberg; Daniel V Catenacci; Atsushi Ohtsu; Kohei Shitara; Ravit Geva; Jonathan Bleeker; Andrew H Ko; Geoffrey Ku; Philip Philip; Peter C Enzinger; Yung-Jue Bang; Diane Levitan; Jiangdian Wang; Minori Rosales; Rita P Dalal; Harry H Yoon
Journal:  JAMA Oncol       Date:  2018-05-10       Impact factor: 31.777

2.  The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.

Authors:  Giandomenico Roviello; Roberto Petrioli; Pietro Rosellini; Andrea Giovanni Multari; Raffaele Conca; Giovanni Paganini; Giorgio Chiriacò; Michele Aieta
Journal:  Invest New Drugs       Date:  2019-01-28       Impact factor: 3.850

3.  Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting.

Authors:  Masayuki Ueno; Akira Doi; Tomohiko Sunami; Hiroshi Takayama; Hirokazu Mouri; Motowo Mizuno
Journal:  J Gastrointest Oncol       Date:  2019-10

4.  Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study.

Authors:  Florian Struller; Philipp Horvath; Wiebke Solass; Frank-Jürgen Weinreich; Dirk Strumberg; Marios K Kokkalis; Imma Fischer; Christoph Meisner; Alfred Königsrainer; Marc A Reymond
Journal:  Ther Adv Med Oncol       Date:  2019-05-13       Impact factor: 8.168

5.  miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.

Authors:  Baohua Fan; Cunfang Shen; Milu Wu; Junhui Zhao; Qijing Guo; Yushuang Luo
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

Review 6.  Late-line treatment in metastatic gastric cancer: today and tomorrow.

Authors:  Elizabeth C Smyth; Markus Moehler
Journal:  Ther Adv Med Oncol       Date:  2019-08-28       Impact factor: 8.168

Review 7.  Recent Developments of Systemic Chemotherapy for Gastric Cancer.

Authors:  Hiroyuki Arai; Takako Eguchi Nakajima
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

8.  Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study.

Authors:  Kailin Ding; Xian Chen; Yong Li; Wenzhu Li; Yongsong Ye; Tingting He; Wenjing Wang; Haibo Zhang
Journal:  Onco Targets Ther       Date:  2021-01-18       Impact factor: 4.147

9.  Long noncoding AFAP1-antisense RNA 1 is upregulated and promotes tumorigenesis in gastric cancer.

Authors:  Fei Ye; Yi Gong; Xiangheng Chen; Meiying Yu; Zhongkun Zuo; Dongni Pei; Wei Liu; Qunwei Wang; Jun Zhou; Lunxi Duan; Leiyi Zhang; Xiaojing Li; Tenglong Tang; Jiangsheng Huang
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

10.  Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status.

Authors:  Runhong Wu; Zhu Shen; Na Yu; Jianhao Xu; Xuya Yuan; Liwei Ni; Yuming Long; Jialong Tao; Yusong Zhang
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.